Investigating LP352 for treating seizures in children and adults with developmental and epileptic encephalopathies
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathies
Run by Longboard Pharmaceuticals · NCT06719141 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new medication called LP352 to see if it can help reduce seizures in children and adults with developmental and epileptic encephalopathies like Lennox-Gastaut Syndrome.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 2 Years to 65 Years |
| Sex | All |
| Enrollment | 320 (estimated) |
| Sponsor | Longboard Pharmaceuticals Industry-sponsored |
| Locations | 109 sites (Little Rock, Arkansas and 108 other locations) |
| Trial ID | NCT06719141 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include children and adults diagnosed with Lennox-Gastaut Syndrome or other forms of developmental and epileptic encephalopathies who meet specific seizure onset and EEG criteria.
✕Probably not a fit
Patients who do not have developmental and epileptic encephalopathies or those whose seizures do not meet the study's inclusion criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study, known as the DEEp OCEAN Study, is a double-blind, randomized, placebo-controlled, multicenter investigation aimed at evaluating the efficacy, safety, and tolerability of LP352 in managing seizures associated with developmental and epileptic encephalopathies (DEE). Participants will undergo a structured process that includes screening, a titration period, a maintenance phase, and a taper period, with the entire study lasting approximately 24 months. The study specifically targets individuals with Lennox-Gastaut Syndrome and other forms of DEE, focusing on their unique seizure profiles and developmental challenges.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients suffering from severe seizures associated with developmental and epileptic encephalopathies.
How similar studies have gone: Other studies investigating treatments for Lennox-Gastaut Syndrome and related conditions have shown promise, indicating that this approach may be beneficial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who are characterized as having Lennox-Gastaut Syndrome (LGS) must fulfill all of the following criteria: * Onset of seizures at ≤8 years old * History of tonic/tonic-atonic seizures plus at least 1 of the following seizure type(s): atypical absence, atonic, myoclonic, focal impaired awareness, generalized tonic-clonic, nonconvulsive status epilepticus, or epileptic spasms * Presence of developmental plateauing or regression * History of electroencephalogram (EEG) showing generalized slow (\<2.5 Hertz \[Hz\]) spike-and-wave complexes * Participants who are characterized as having DEE (Other) must fulfill all of the following criteria: * Does not meet criteria for LGS * Onset of seizures at ≤5 years old * Presence of developmental plateauing or regression * History of multiple seizure types * History of interictal EEG background showing diffuse or multifocal slowing (with or without epileptiform activity) * The participant has a current occurrence of at least 1 of the following countable motor seizure types: generalized tonic-clonic, tonic (bilateral), clonic (bilateral), atonic (bilateral) with truncal/leg involvement, focal motor (including hemiclonic), and focal to bilateral tonic-clonic. * The participant has demonstrated an average of at least 4 countable motor seizures per month for each of the 3 months prior to Screening. * The participant has been taking 1 to 4 antiseizure medications (ASMs) at a stable dose for at least 4 weeks prior to Screening. * The participant, parent, or caregiver is willing and able (in the judgment of the investigator) to comply with completion of the diaries throughout the study. * The participant must be willing and able to provide written informed consent; in instances where the participant is unable to provide consent, an appropriate legal representative. Exclusion Criteria: * The participant has a diagnosis of Dravet Syndrome (DS) or has a mutation of the Sodium channel protein type 1 subunit alpha (SCN1A) gene consistent with DS. * The participant has been admitted to a medical facility for treatment of status epilepticus requiring mechanical ventilation within 3 months prior to Screening. * The participant has a neurodegenerative disorder as indicated by magnetic resonance imaging or genetic testing. * The participant has an acquired lesion/injury unrelated to the primary etiology that could contribute as a secondary cause of seizures. * The participant is receiving exclusionary medications. * The participant is currently using any cannabis product or cannabidiol that is not in oral solution/capsule/tablet form, not obtained from a government-approved dispensary, or contains ≥50% Delta-9-tetrahydrocannabinol (THC). * The participant has unstable, clinically significant neurologic (other than the disease being studied; eg, recurrent strokes), psychiatric, cardiovascular (eg, pulmonary arterial hypertension, cardiac valvulopathy, orthostatic hypotension/tachycardia), pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, hematopoietic, or endocrine disease or other abnormality which may impact the ability of the participant to participate or potentially confound the study results. * The participant is unable or unwilling to comply with any of the study requirements or timelines.
Where it's running
-
Arkansas Children's Hospital - PIN
Little Rock, Arkansas, United States Recruiting -
Children's Hospital Los Angeles - PIN
Los Angeles, California, United States Recruiting -
David Geffen School of Medicine at UCLA
Los Angeles, California, United States Recruiting -
The Stanford Division of Child Neurology
Palo Alto, California, United States Recruiting -
UCSF Children's Hospital
San Francisco, California, United States Recruiting -
Children's Hospital Colorado.
Aurora, Colorado, United States Recruiting
Show 44 more locations
-
Children's National Medical Center
Washington D.C., District of Columbia, United States Recruiting -
NW FL Clinical Research Group, LLC
Gulf Breeze, Florida, United States Recruiting -
University of Miami - 1120 NW 14th St
Miami, Florida, United States Recruiting -
Nicklaus Children's Hospital - PIN
Miami, Florida, United States Recruiting -
University of South Florida - 2 Tampa General Circle
Tampa, Florida, United States Recruiting -
Pediatric Epilepsy and Neurology Specialists
Tampa, Florida, United States Recruiting -
Children's Healthcare of Atlanta - Center for Advanced Pediatrics - PIN
Atlanta, Georgia, United States Recruiting -
Consultants In Epilepsy and Neurology PLLC
Boise, Idaho, United States Recruiting -
Ann and Robert H Lurie Childrens Hospital of Chicago - PIN
Chicago, Illinois, United States Recruiting -
University of Iowa Hospitals & Clinics - (CRS)
Iowa City, Iowa, United States Recruiting -
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland, United States Recruiting -
Massachusetts General Hospital - 175 Cambridge St
Boston, Massachusetts, United States Recruiting -
Mayo Clinic - PIN
Rochester, Minnesota, United States Recruiting -
Institute of Neurology and Neurosurgery at Saint Barnabas, LLC
Livingston, New Jersey, United States Recruiting -
Northeast Regional Epilepsy Group - Morristown - 310 Madison Ave
Morristown, New Jersey, United States Recruiting -
NYU Comprehensive Epilepsy Center - BRANY - PPDS
New York, New York, United States Recruiting -
Oregon Health and Science University
Portland, Oregon, United States Recruiting -
Le Bonheur Childrens Outpatient Center - PIN
Memphis, Tennessee, United States Recruiting -
Child Neurology Consultants of Austin - 6811 Austin Center Blvd
Austin, Texas, United States Recruiting -
Cook Children's Jane and John Justin Neurosciences Center - PIN
Fort Worth, Texas, United States Recruiting -
The University of Texas Medical School at Houston
Houston, Texas, United States Recruiting -
Multicare Health System - Mary Bridge Pediatrics
Tacoma, Washington, United States Recruiting -
Prince of Wales Hospital
Randwick, New South Wales, Australia Recruiting -
Sydney Children's Hospital
Randwick, New South Wales, Australia Recruiting -
Children's Hospital at Westmead
Westmead, New South Wales, Australia Recruiting -
Royal Brisbane & Women's Hospital
Herston, Queensland, Australia Recruiting -
Queensland Children's Hospital
South Brisbane, Queensland, Australia Recruiting -
Austin Hospital
Heidelberg, Victoria, Australia Recruiting -
Royal Children's Hospital Melbourne
Parkville, Victoria, Australia Recruiting -
The Alfred Hospital
Melbourne, Australia Recruiting -
UZ Antwerpen
Edegem, Antwerpen, Belgium Recruiting -
UZ Leuven - PPDS
Leuven, Belgium Recruiting -
Instituto de Neurologia de Curitiba (INC)
Curitiba, Paraná, Brazil Recruiting -
Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP - PPDS
Ribeirão Preto, São Paulo, Brazil Recruiting -
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS
São José do Rio Preto, São Paulo, Brazil Recruiting -
Instituto de Psiquiatria HC FMUSP
São Paulo, Brazil Recruiting -
Children's and Women's Health Centre of British Columbia-4480 Oak St
Vancouver, British Columbia, Canada Recruiting -
London Health Sciences Centre -800 Commissioners Rd E
London, Ontario, Canada Recruiting -
Peking University First Hospital - Daxing Campus
Beijing, Beijing Municipality, China Recruiting -
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China Recruiting -
Shenzhen Children's Hospital
Shenzhen, Guangdong, China Recruiting -
Wuhan Children's Hospital
Wuhan, Hubei, China Recruiting -
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China Recruiting -
Beijing Children's Hospital, Capital Medical University - PIN
Beijing, China Recruiting
+59 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Email contact via H. Lundbeck A/S
- Email: HQ_Medinfo@Lundbeck.com
- Phone: +45 36301311
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding Developmental and Epileptic Encephalopathy through Clinical Data
This study is trying to gather and analyze health information from patients with Developmental and Epileptic Encephalopathy to better understand the condition and improve treatment options.
-
Understanding Pyrimidine and Purine Metabolism Disorders
This study is trying to learn more about pyrimidine and purine metabolism disorders by comparing affected people with their healthy family members to see what factors might influence their condition.
-
Multi-biomarkers in DEE: a big look at genetic epilepsies
This study tests a panel of multi-omic biomarkers in people with genetically confirmed Developmental and Epileptic Encephalopathy to help understand prognosis and potential biomarkers for future therapies.
-
SLC6A1-NDD: A Longitudinal Look at How the Disorder Progresses
This study follows children and young people with SLC6A1-NDD over two years to see how the condition changes over time and to test which assessments work for future research.
-
S230815 for children with KCNT1-related developmental and epileptic encephalopathy
This study will test whether the investigational medicine S230815 is safe, well tolerated, and affects seizures and related symptoms in children aged 2–12 who have KCNT1-related developmental and epileptic encephalopathy.
-
Elsunersen treatment for infants with early-onset SCN2A-related epileptic encephalopathy
This trial tests whether elsunersen can reduce seizures and is safe in infants and young children with early-onset SCN2A-related developmental and epileptic encephalopathy who have gain-of-function variants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.